No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS) | SpringerLink
More Evidence Backing Anti-CDK4/6-Based Therapy in Recurrent Endometrial Cancer | MedPage Today
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
CDK4-6-Hemmer zur Verbesserung der Tumorkontrolle – Rosenfluh.ch
Kaplan–Meier curve for overall survival in the premenopausal population... | Download Scientific Diagram
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study - Annals of Oncology
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
Progression-free survival (PFS) in the PALOMA-1 phase II trial... | Download Scientific Diagram
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library
Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram
K-M curve and parametric survival distributions for OS. OS, overall... | Download Scientific Diagram
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | Journal of Clinical Oncology
Progression-free survival (intention-to-treat population) in subgroups... | Download Scientific Diagram
